Omega Therapeutics presents new preclinical data at ASGCT 2024

Omega Therapeutics announced the presentation of new preclinical data demonstrating durable and tunable bidirectional regulation of gene expression in cellular models at the pre-transcriptional level at the American Society of Gene and Cell Therapy, ASGCT, 27th Annual Meeting, taking place in Baltimore, Maryland, May 7 – 11. “These exciting new data underscore the versatile capabilities and power of our OMEGA platform,” said Thomas McCauley, Ph.D., Chief Scientific Officer of Omega Therapeutics. “We have demonstrated preclinically that we can prospectively engineer epigenomic controllers to predictably and durably upregulate gene expression across a diverse range of gene types, including turning on inactivated genes, augmenting the expression of genes with low baseline expression levels, and leveraging existing genomic regulatory processes to boost expression. These capabilities unlock a wide spectrum of possibilities to apply precision epigenomic control as a novel therapeutic modality to meaningfully address key drivers of many diseases.”